CFO of Progenics Pharmaceuticals Inc. (PGNX, Financial) Robert A Mckinney sells 4,000 shares of PGNX on 06/18/2010 at an average price of $6.25 a share.
Progenics Pharmaceuticals Inc. has a market cap of $196.34 million; its shares were traded at around $6.06 with and P/S ratio of 4.01. Progenics Pharmaceuticals Inc. had an annual average earning growth of 5.6% over the past 10 years.
PGNX is in the portfolios of Paul Tudor Jones of The Tudor Group, Jim Simons of Renaissance Technologies LLC.
Progenics Pharmaceuticals Inc. has a market cap of $196.34 million; its shares were traded at around $6.06 with and P/S ratio of 4.01. Progenics Pharmaceuticals Inc. had an annual average earning growth of 5.6% over the past 10 years.
PGNX is in the portfolios of Paul Tudor Jones of The Tudor Group, Jim Simons of Renaissance Technologies LLC.
CEO Recent Trades:
- Buy: CEO/CSO Paul J Maddon bought 5,000 shares of PGNX stock on 06/01/2010 at the average price of 4.99. Paul J Maddon owns at least 824,057 shares after this. The price of the stock has increased by 21.44% since.
- Buy: CEO/CSO Paul J Maddon bought 5,000 shares of PGNX stock on 05/20/2010 at the average price of 4.93. Paul J Maddon owns at least 819,057 shares after this. The price of the stock has increased by 22.92% since.
Directors and Officers Recent Trades:
- Sell: Sr. VP, Medical Affairs Robert J Israel sold 7,056 shares of PGNX stock on 03/18/2010 at the average price of 5.37. Robert J Israel owns at least 36,842 shares after this. The price of the stock has increased by 12.85% since.
- Sell: President Mark Robert Baker sold 2,165 shares of PGNX stock on 03/18/2010 at the average price of 5.33. Mark Robert Baker owns at least 28,423 shares after this. The price of the stock has increased by 13.7% since.
